Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLX090-Tx in Metastatic Bone Pain
NCT07197645Phase 1Recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of samarium-153-dotmp in bone metastases and bone pain, sponsored by Telix Pharmaceuticals Limited. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 6 weeks. Started Oct 2025; status: recruiting.
02
Drugs
samarium-153-dotmp
03
Conditions
bone metastasesbone pain
Beyond the preview
Go deeper on NCT07197645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197645.